The organosilicon chemical trimethylsilanol has the formula (CH3)3SiOH. The Si (Silicon) center accepts three methyl groups and one hydroxyl group. It is a colorless, volatile liquid. Due to its composition and molecular structure, the organosilicon compound possesses the qualities of organic substances and the functions of inorganic substances, giving organosilicon materials outstanding properties. Organosilicon compounds have been employed in many different industries, including construction, electronics, textiles, automotive, cosmetics, personal care, and military and defense. Aerospace and healthcare are two new industries that have seen an increase in demand for organosilicon compounds. Due to all these reasons, according to OMR Research, the market is expected to grow at a CAGR of 2.4% during the forecast period (2022–2028).
Segments of the Market
The global trimethylsilanol market is segmented on the basis of type and application. On the basis of type, the market is sub-segmented into 99% purity, 98% purity, and others. Further, on the basis of application, it is sub-segmented into silicone rubber, pharmaceuticals, and others such as chemicals, automotive, healthcare, and renewable energy.
Recent Developments
AbbVie Pty Ltd., AstraZeneca Pty Ltd., Amgen Australia Pty Ltd., Evonik, LIBERTY Steel Group, Wacker Chemie, Thermo Fisher Scientific, Inc. (Alfa Aesar), Merck KGaA (Sigma-Aldrich Co.), Wilshire Technologies (Evonik Company), Gelest, and other market players are contributing to the market’s growth via various mergers, acquisitions, investments, and new product launch activities. Some of the recent developments in the market, through direct players and end users, include:
• In July 2022, AkzoNobel announced its plan to invest $21.2 million to increase and improve production at two of its sites in France. The company will invest $15.9 million in the company’s aerospace coatings facility in Pamiers, and the other $5.3 million will be spent on improving production flexibility at the decorative paints site in Montataire.
• In October 2021, Evonik Industries AG, a chemical company, and Wynca Group formed a joint venture with the name "Evonik Wynca (Zhenjiang) Silicon Material Co., Ltd." The joint venture aims to start a new fumed silica plant.
• In February 2021, AZO Materials developed two products: sperfluoro-octyl-trichlorosilane (FOTS)-trimethylsilanol (TMS) self-assembled monolayer (SAM) and Cytop-TMS spin-coated thin film.
• In April 2021, chemical engineers at MIT introduced a new method for incorporating hydrophobic drugs into tablets or other drug formulations. For this, the engineers use methyl derivatives such as trimethylsilanol, methylcellulose, and others as excipients with nanocrystals in the nanoemulsion process.
• In January 2020, Evonik, the German specialty chemicals company, acquired the phytochemical company, Wilshire Technologies. Wilshire supplies natural actives and derivatives to the global cosmetics and pharmaceutical industries.
• In December 2020, Thermo Fisher Scientific announced the expansion of its footprint in Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies, and vaccines. As a part of its expansion plan, the company is expanding its capacity at the Ferentino and Monza sites in Italy. The company’s investments in these sites will add good manufacturing practice (cGMP) commercial production lines, which will support a range of capabilities, including live virus, aseptic liquid, and lyophilized vial filling.
Conclusion
Trimethylsilanol can be utilized as the primary component of exceptionally hard and weatherable coatings, or it can be mixed with organic resins to make hybrid materials with better heat resistance in automobiles, footwear, and electronics. Trimethylsilanol is also used in the pharmaceutical industry for the drug development process. Hence, the growing pharmaceutical industry will bolster the market’s growth. According to the Congressional Budget Office (CBO), as of April 2021, the pharmaceutical companies operating in the US spend over 21.0% of their revenues on R&D, or drug development programs. In addition, the R&D expenditure of the US pharmaceutical industry was estimated to be around $102 billion in 2021. Due to all such factors, the global trimethylsilanol market will grow during the forecast period.